X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4307) 4307
Publication (691) 691
Book Review (96) 96
Book Chapter (71) 71
Dissertation (15) 15
Conference Proceeding (4) 4
Book / eBook (3) 3
Data Set (2) 2
Magazine Article (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nonalcoholic steatohepatitis (3078) 3078
index medicus (2573) 2573
humans (2239) 2239
male (1586) 1586
gastroenterology & hepatology (1407) 1407
nonalcoholic fatty liver disease (1275) 1275
fatty liver (1175) 1175
animals (1172) 1172
female (1150) 1150
liver (1129) 1129
insulin-resistance (1103) 1103
liver diseases (1088) 1088
obesity (1029) 1029
fatty liver-disease (976) 976
fibrosis (912) 912
metabolic syndrome (902) 902
insulin resistance (859) 859
liver - pathology (828) 828
middle aged (827) 827
mice (765) 765
adult (744) 744
disease (708) 708
steatohepatitis (698) 698
steatosis (698) 698
non-alcoholic fatty liver disease (695) 695
risk factors (688) 688
liver - metabolism (681) 681
inflammation (666) 666
hepatic steatosis (630) 630
oxidative stress (616) 616
fatty liver - pathology (593) 593
nonalcoholic fatty liver (569) 569
nash (513) 513
gastroenterology and hepatology (500) 500
rodents (479) 479
digestive system diseases (476) 476
nutritional and metabolic diseases (451) 451
metabolism (448) 448
prevalence (442) 442
biopsy (426) 426
fatty liver - metabolism (419) 419
nafld (419) 419
non-alcoholic fatty liver disease - pathology (412) 412
hepatology (411) 411
medicine (410) 410
diabetes (408) 408
diet (406) 406
article (405) 405
cirrhosis (405) 405
research (388) 388
hepatocellular-carcinoma (380) 380
analysis (378) 378
disease models, animal (365) 365
mice, inbred c57bl (361) 361
aged (358) 358
non-alcoholic fatty liver disease - metabolism (348) 348
research article (347) 347
lipids (342) 342
liver cirrhosis (342) 342
digestive system (339) 339
health aspects (339) 339
biochemistry & molecular biology (330) 330
expression (317) 317
natural-history (312) 312
gene expression (310) 310
pathogenesis (309) 309
hepatitis (307) 307
multidisciplinary sciences (307) 307
diagnosis (306) 306
endocrinology & metabolism (301) 301
care and treatment (298) 298
fatty acids (298) 298
fatty liver - etiology (295) 295
rats (292) 292
hepatocellular carcinoma (290) 290
review (288) 288
gastroenterology (287) 287
physiological aspects (282) 282
risk-factors (280) 280
body mass index (279) 279
disease progression (275) 275
insulin (272) 272
development and progression (269) 269
apoptosis (261) 261
liver - drug effects (260) 260
nutrition & dietetics (260) 260
cholesterol (259) 259
medicine, research & experimental (257) 257
fatty liver - complications (252) 252
liver cirrhosis - pathology (247) 247
science (247) 247
medicine & public health (244) 244
lipid metabolism (236) 236
biomarkers - blood (235) 235
liver cancer (229) 229
pharmacology & pharmacy (226) 226
association (225) 225
proteins (223) 223
non-alcoholic steatohepatitis (222) 222
obesity - complications (219) 219
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4233) 4233
Korean (59) 59
Japanese (40) 40
German (15) 15
French (10) 10
Chinese (8) 8
Polish (4) 4
Spanish (4) 4
Russian (3) 3
Portuguese (2) 2
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 01/2017, Volume 37, Issue S1, pp. 97 - 103
The hallmark of non‐alcoholic fatty liver disease ( NAFLD ) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic... 
FXR | glucagon‐like peptide | NAFLD | 1) agonist | farnesoid X receptor | peroxisome proliferator‐activator receptor | GLP | NASH | non‐alcoholic steatohepatitis | agonists | PPAR | non‐alcoholic fatty liver disease | ROS | reactive oxygen species | non-alcoholic fatty liver disease (NAFLD) | farnesoid X receptor (FXR) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | ROS (reactive oxygen species) | non-alcoholic steatohepatitis (NASH) | VITAMIN-E | ACID | RANDOMIZED-TRIALS | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | WEIGHT-LOSS | GLUCAGON-LIKE PEPTIDE-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | PENTOXIFYLLINE | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article
Journal Article
Journal of Functional Foods, ISSN 1756-4646, 07/2014, Volume 9, Issue 1, pp. 48 - 59
Nonalcoholic steatohepatitis (NASH) is a form of chronic progressive liver disease wherein patients appear to have a higher likelihood of progression to... 
Catechins | Nonalcoholic steatohepatitis | Green tea | Dietary | Exercise therapy | FIBROSIS | METABOLIC SYNDROME | OXIDATIVE STRESS | FATTY LIVER-DISEASE | FOOD SCIENCE & TECHNOLOGY | MARKERS | SERUM | POLYPHENOLS | INSULIN-RESISTANCE | MICE | EPIGALLOCATECHIN-3-GALLATE
Journal Article
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, ISSN 0867-5910, 10/2009, Volume 60, Issue 3, pp. 71 - 75
Nonalcoholic steatohepatitis (NASH) represents one of the most common liver diseases. It is strongly associated with obesity and insulin resistance and is... 
FIBROSIS | adiponectin | METABOLIC SYNDROME | PHYSIOLOGY | FATTY LIVER-DISEASE | ALPHA | leptin | nonalcoholic steatohepatitis | interleukin 6 | OBESITY | tumor necrosis factor alpha | INSULIN-RESISTANCE | INFLAMMATION | resistin | insulin resistance | SEVERITY | Interleukin 6 | Nonalcoholic steatohepatitis | Leptin | Insulin resistance | Tumor necrosis factor a | Adiponectin | Resistin
Journal Article
Journal Article